[Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition].
Hedner
Thomas
T
Sahlgrenska akademin, Göteborg.
Melander
Arne
A
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002074:Butanones / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D000077430:Nabumetone; D012307:Risk Factors; D013450:Sulfones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D000077430:Nabumetone